Abstract: Ruptures of macrophage-rich atherosclerotic plaques in the coronary arteries are the main reason for heart attack. Targeted therapeutic interventions with an inhibitory effect on the macrophages promise to be beneficial, but currently available drugs such as statins achieve event reductions of only 30%. Dose-limiting adverse effects in remote organs prohibit achieving higher drug levels known to have strong inhibitory effects on macrophages. Receptor-specific targeting using statin-loaded nanometer-sized triblock copolymer vesicles with targeting moieties might allow high-dose treatment for improved efficacy, while minimizing toxicity in other cells. Vesicle uptake by target cells but not other cell types and slow intracellular content release was observed. A major improvement in biologic efficacy was observed for polymer vesicles compared to free drug, whereas no increased cytotoxicity was observed in muscle cells. Such high-dose, targeted therapy of statins through cell-specific polymer vesicles allows novel treatment paradigms not only for atherosclerosis, but appears promising for a wide range of drugs and diseases.
I n recent years, ample evidence has accumulated supporting the hypothesis that local and systemic inflammatory processes play a key role in the pathogenesis of atherosclerotic diseases. [1] [2] [3] Activated macrophages initiate, maintain, and aggravate the various steps that finally lead to plaque rupture and vessel occlusion, the most common pathophysiological equivalent of myocardial infarction and stroke. 4, 5 The amount of macrophages in a plaque correlates directly with the risk of plaque rupture, making the macrophage and inflammatory plaques important therapeutic targets in cardiovascular medicine. 3, 6 Anti-inflammatory drugs such as corticosteroids, calcineurin inhibitors, or cyclooxygenase inhibitors are not suitable for a selective inhibition of active plaque macrophages due to their low cell line selectivity and serious side effects. An ideal drug candidate would accumulate in highly active plaque macrophages, thereby sparing inactive macrophages, monocytes and other nontargeted cell types.
Lipid-lowering drugs of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor class have partial anti-inflammatory and immunomodulatory properties 7, 8 and lead to a~30% reduction of acute cardiac events. 9, 10 In macrophages, statins exhibit several effects [11] [12] [13] that in combination lead to a reduced uptake of oxidized low-density lipoprotein (LDL), reduced secretion of leucotactic and tissuedegrading molecules, 14 and in consequence a reduced number of plaque ruptures and acute coronary syndromes. 15 These immunomodulatory effects are concentration dependent, whereby high concentrations of statins exhibit the most significant inhibition of macrophage activity and proliferation. 16 Furthermore, high-dose statins can directly downregulate the expression of scavenger receptor class A in macrophages by increasing the intracellular levels of transforming growth factor (TGF)-b1. 17 Statin concentrations used in this kind of receptor inhibition experiments (10 mmol/L), however, can never be achieved in humans without having life-threatening adverse side effects such as rhabdomyolysis (mean peak plasma concentration for 40 mg oral pravastatin per day is 7.17 nmol/L). 18 By targeting the drugs specifically to macrophages populating the atherosclerotic plaques, the high-dose toxicity of statins might be circumvented and the immunomodulatory effects might be fully exploited. 19 Nanometer-sized vesicles self-assembled from biocompatible, protein-repellent and immune system evading amphiphilic block copolymers promise to be useful for selective delivery, 20 triggered activity, 21 and controlled release of high doses of therapeutic agents. 22 The copolymers form vesicles in aqueous solution and enclose a defined part of the dissolved drug molecules. Recently, it has been shown that the number of encapsulated molecules can simply be calculated from the original bulk concentration and the volume of the vesicles. 23 By functionalizing the vesicle surface with chemical targeting moieties, the nanostructures can be directed to specific cellular targets. In a previous study, the same targeted polymer vesicles made from (poly(2-methyloxazoline)-b-poly(dimethylsiloxane)-b-poly(2-methyloxazoline) triblock copolymers were filled with fluorescent markers to study the targeting properties, uptake kinetics, and toxicity in cell cultures of scavenger receptor A1-expressing transgenic cell lines, human THP-1 macrophages, human smooth muscle cells and human endothelial cells. The vesicles were target specific to scavenger receptor expressing cells and macrophages, whereas no uptake to the other investigated cell lines or THP-1 macrophage precursor cells was observed. The targeted polymer vesicles did not exhibit significant toxic effects on both cells taking up and not taking up the vesicles. 20 Here, we present the use of the receptor targeted polymer vesicles for encapsulation of the hydrophilic drug pravastatin. Pravastatin has a proven inhibitory effect on macrophage endocytotic activity and metabolism in cell cultures and in vivo. 15 The vesicles were functionalized with an oligonucleotide sequence (polyG) with a proven affinity to macrophage scavenger receptor A1 (SRA-1) and tested in cell cultures of human macrophages for efficacy, substance release properties, and toxicity compared to nonencapsulated pravastatin and empty polymer vesicles. Cell-line specificity and myocyte toxicity were tested in cell cultures of rat skeletal muscle cells. The myocytes are known to be sensitive to statins and are a valid model for statin toxicity prediction. 24 
METHODS

Pravastatin Vesicle Preparation
The polymer used in this work consists of a poly (dimethylsiloxane) (PDMS) middle block and two poly(2-methyloxazoline) PMOXA side chains (JW05, M n 7090 g/mol) 25 with biotin-functionalized end groups as described previously. 20 To prepare the vesicles, the polymer (10% biotinylated, 90% unbiotinylated polymer) was dissolved in ethanol to give a 15% (wt/vol) solution; 250 mL of this ethanol solution was added dropwise into 5 mL of phosphate-buffered saline (PBS) containing 1.12 mmol/L pravastatin (SigmaAldrich, Buchs, Switzerland). After 4 h of continuous stirring, the solution was repetitively filtrated through filters of defined pore size (Millex-GV, 0.45 mm and 0.22 mm; Millipore) to produce a homogenous population of vesicles. Nonencapsulated pravastatin was removed chromatographically (Sepharose 4B, Sigma-Aldrich, in a 37-cm column with 1 cm inner diameter, Bio-Rad, Reinach, CH). To obtain ligand-bearing vesicles, 4 mmol/L streptavidin (Sigma-Aldrich) followed by 4 mmol/L biotinylated polyguanylic acid (polyG; Microsynth, Balgach, CH; 23 G, 3# modified with biotin) were added (2 h each with continuous stirring). To produce fluorescencelabeled polymer vesicles, Alexa-610 streptavidin (Invitrogen, Basel, Switzerland) was used instead of unlabeled streptavidin. Vesicles were characterized as described earlier with light scattering and cryogenic transmission electron microscopy. 
Cellular Uptake of Vesicles
Alexa-610 labeled polymer vesicles were administered to cell cultures of macrophages and skeletal muscle cells as described previously 20 for 2 hours in a final concentration of 4 nmol/L vesicles. Cell nuclei were stained with 18 mmol/L Hoechst 34580 (Invitrogen; stock solution with dimethyl sulfoxide) for 30 min.
Endocytotic Activity Assay
Polymer vesicles were added to the prepared macrophage cultures for 24 hours with final pravastatin concentrations in the medium from 0.02 mmol/L to 1.08 mmol/L. Alexa-488-labeled acetyled LDL (Invitrogen) or labeled polyG (same as above coupled to streptavidin-phycoerythrin from SigmaAldrich in a 1:1 proportion) were added for 1 h in final concentrations of 20 mmol/L and 1 mg/mL, respectively to test the endocytotic activity. After washing with PBS, the cells were fixed in 4% paraformaldehyde for 20 min at room temperature. Fixed cells were mounted with an antibleaching glycerolbased mounting medium (Sigma-Aldrich) on glass slides.
Calcein Release Assay
Calcein (Sigma-Aldrich) was encapsulated into functionalized vesicles as described above in a high self-quenching concentration of 50 mmol/L and checked for absence of fluorescence signal in fluorescence microscopy. Polymer vesicles were given to cultures of macrophages for different time points in a working concentration of 4 nmol/L. An intact carrier does not generate a significant signal in fluorescence microscopy due to the self-quenching properties of encapsulated calcein, whereas the generation of a signal indicates the disintegration of the carrier. Ratio of cells with significant green fluorescence (higher than background fluorescence) in the sample compared to total number of cells seen by phase contrast microscopy was taken as parameter for the integrity of the polymer vesicles (no fluorescence indicates intact vesicles).
Cytotoxicity Assay
Cytotoxicity in macrophages was studied with an acetoxymethyl (AM) ester derivate of calcein (1 mmol/L in DMSO; Invitrogen). Macrophages were incubated with polymer vesicles containing pravastatin or PBS and compared to controls. After 24 hours of incubation, the cells were washed with PBS and exposed to 1 mmol/L calcein AM for 60 min. The lipophilic, nonfluorescent calcein AM is hydrolyzed inside living cells by nonspecific esterases and stains selectively living cells. To assess the known toxic effects of pravastatin on skeletal muscle cells, we additionally performed a colorimetric LDH release assay (Sigma-Aldrich) in 96-well multiwell plates to confirm the results from the Calcein AM release assay. 26 Dead cells release intracellular LDH into the serum-free medium, where it is detected with a standard 
Data Acquisition and Statistics
Cells were examined using fluorescence microscopy (Olympus IX 50, Camera ColorView II FW, Software analySIS) and confocal laser scanning microscopy (Zeiss ConfoCor 2, HAL 100, HBO 100, Software LSM 510 Zeiss) by selecting multiple random fields of view in an unbiased way. Image acquisition settings were unchanged over the whole experiment. Digital images were treated according to Nature's guide for digital images (Nature Publishing Group, UK). The resulting series of images were analyzed by standard data analysis software (ImageJ, National Institutes of Health, Bethesda, MD) with automated particle counting to determine the number of cells per field of view whenever necessary. Standard statistics were used, including calculation of means and standard deviations (SD), linear regression, least square fitting to the sigmoid function for determination of ED50, application of analysis of variance (ANOVA), and Student's t test for group comparisons.
RESULTS
Polymer Vesicle Characterization
Polymer vesicles with encapsulated pravastatin (Fig. 1) show a mean outer diameter of 97 nm (standard deviation 10 nm) in cryogenic transmission electron microscopy, whereof the inner diameter is 72 nm (SD 14 nm) . 25 the total inner volume of all vesicles in 1 mL solution is 8.01 mL. Since the pravastatin encapsulated into the polymer vesicles has the same concentration as the initial bulk solution (1.12 mmol/L), it is possible to calculate the mean pravastatin concentration of the solution after chromatographic removal of all non-encapsulated pravastatin. The calculated pravastatin concentration in the resulting vesicle solution is 8.97 mmol/L.
Targeting of Polymer Vesicles
Polymer vesicles functionalized with polyG ligands show a strong uptake into active macrophages, but were not taken up in significant numbers into skeletal muscle cells due to their target selectivity to class A scavenger receptors ( Fig.  2A and B) . After 2 hours, the fluorescence-labeled vesicles can FIGURE 1. Vesicle characterization. A, Schematic drawing of a ligandfunctionalized amphiphilic triblock copolymer vesicle with encapsulated pravastatin. B, Vesicles were visualized with cryogenic transmission electron microscopy. The images show a highly homogenous population of vesicles with a mean diameter slightly below 100 nm and an aqueous core. C, Detail of (B).
be found in intracellular compartments of macrophages, most probably endolysosomes (Fig. 2C) .
Inhibition of Endocytotic Activity
Fluorescence-labeled acetylated LDL (ac-LDL) was used to determine the effect of vesicle-encapsulated pravastatin on the endocytotic activity of macrophages. When treated with pravastatin-containing polymer vesicles for 24 hours, the macrophages showed a decreased endocytotic activity compared to cells treated with empty vesicles and untreated cells (Fig. 3) . The effect on the activity was dependent on the concentration of pravastatin and the ED50 (dosage that produces a significant reduction of endocytotic uptake in half of the cell population) was 0.25 mmol/L final pravastatin concentration in the cell culture medium (Fig. 4A) . The same experiments were performed with the fluorescence-labeled oligonucleotide polyG as an activity marker. Here, the effect was comparable to ac-LDL and the ED50 was 0.15 mmol/L final pravastatin concentration in the cell culture medium (Fig. 4B) . These results confirm the equivalence of polyG as a marker for macrophage endocytotic activity. The ED50 for ligand uptake inhibition with nonencapsulated pravastatin was 11 mmol/L (final concentration of pravastatin in the cell culture medium). Empty targeted polymer vesicles that did not contain any drugs did not influence the endocytotic competence of macrophages significantly (Fig. 4C) , indicating that the observed effect of vesicle-encapsulated pravastatin is only caused by the drug itself and not by the polymeric carrier.
Substance Release Assay
To investigate the substance release properties of the polymer vesicles inside the macrophages, the calcein release assay was used (see Methods for details). Experiments with different time points showed that the polymer vesicles remained intact for as long as 6 to 12 hours inside the macrophages (Fig. 4D) . Between 12 hours and 36 hours, there was a gradual increase of fluorescent signal, indicating a continuous release and deposition of the dye inside the cell (Fig. 2D) . The results indicate further that the polymer vesicles are biodegradable and show sustained release properties, features that render the results gained in experiments with pravastatincontaining vesicles even more valuable.
Toxicity Assay
To explore possible toxic effects, we exposed standardized cell cultures of macrophages to high concentrations of both pravastatin-containing polymer vesicles and empty vesicles for 24 hours. After 24 hours, 63% (SD 19.6%) of the untreated macrophages were vital, whereas cells treated with 10% ethanol showed a survival rate of 2.9% (SD 0.75%; P , 0.01, always versus untreated control). Treatment with a high concentration of 10 nmol/L polymer vesicles resulted in a survival rate of 54% (SD 15.2%; P = 0.40) for pravastatinloaded vesicles and 57.9% (SD 16.7%; P = 0.68) for empty vesicles, respectively.
Cell cultures of rat skeletal muscle cells were incubated with free pravastatin or pravastatin-containing polymer vesicles to compare their effect on cell survival. Treatment with high concentrations of free pravastatin leads to significant acute toxic effects on the muscle cells in two different assays (Fig. 5) . Viability decreased at concentrations of 2 to 3 times ED50, and at a concentration of 10-fold ED50 (corresponding to 110 mmol/L pravastatin in medium), only 12.5% (SD 6.4%; P , 0.01) of the cells remained viable after 24 hours. Ligand-functionalized polymer vesicles on the other hand lead to no significant increase in cell death up to 15-fold ED50.
DISCUSSION
We showed that receptor-targeted polymer vesicles can be used for safe encapsulation and highly efficient delivery of pravastatin and controlled intracellular release of encapsulated hydrophilic substances. With this novel delivery tool, it is possible to inhibit the endocytotic activity of macrophages defined by the uptake of known scavenger receptor ligands. With free pravastatin, the same effect can only be achieved with much higher doses that would lead to life-threatening side effects in humans. Polymer vesicles with or without encapsulated pravastatin exhibit no toxic effects in cell cultures in high concentrations and are known to be stable and targetspecific drugs delivery tools. Due to their protein-repellent polymeric surface layer and specific ligand functionalization, the vesicles are only taken up by the desired target cell, but not by other cell types that might cause side effects in organisms.
After uptake into macrophages, the polymer vesicles are gradually degraded in intracellular compartments and release their encapsulated load in a time-dependent way. Released drug molecules such as pravastatin reach instantly the cytosol and can exhibit strong effects on cell metabolism and immunological activity.
Until now, statins have scarcely been administered in controlled release or drug delivery formulations [27] [28] [29] due to their overall low toxicity when used in lipid-lowering concentrations. However, the application of higher doses seems to be profitable for the treatment of inflamed vulnerable plaques and is only limited by the adverse side effects. Encapsulation of extremely high doses of statins into target-specific polymeric vesicles promises to be useful for a selective inhibition of highly active macrophages in vulnerable plaques. However, the current study has several important limitations that have to be investigated in future experiments. At the moment, the targeted polymer vesicles were only tested in cell cultures and there are no published results about the behavior of this type of polymer vesicles in animals. Crucial points for future experiments are in vivo targeting and biodistribution, biodegradability, efficacy, and short-term and long-term toxicity. Furthermore, in the current experimental setup, we only studied the effects of vesicle targeted pravastatin on the endocytotic activity of macrophages. In future, it will be interesting to see the effect of this treatment on cytokine production, cell motility, and survival and other important FIGURE 4. Inhibition of endocytotic activity and substance release. A, Quantification of the endocytosis inhibitory effect of pravastatin-containing polymer vesicles was performed with different drug concentrations. Macrophages with a significant (stronger than background) uptake of labeled ac-LDL were taken as quantification parameter. The necessary drug concentration to inhibit the endocytotic uptake of ac-LDL by 50% (ED50) is 0.25 mmol/L. B, The same experiment as in a) was repeated with the labeled oligonucleotide polyG instead of ac-LDL as an activity marker. For free pravastatin, ED50 is 11 mmol/L, whereas for the polymer vesicles containing pravastatin the ED50 is only 0.15 mmol/L. C, The effect on polyG uptake of pravastatin-containing polymer vesicles was compared to empty polymer vesicles. Pravastatin-containing polymer vesicles show again a strong inhibition of endocytotic activity, whereas empty vesicles exhibit no significant inhibitory effect on macrophage endocytosis. The results indicate that the inhibition of endocytotic activity is mainly due to the drug molecule and not due a blockade of scavenger receptors with the polymer vesicles. D, Release of self-quenching calcein from polymer vesicles inside the macrophages indicates the integrity of the vesicles. No fluorescence inside the cells indicates intact vesicles; strong green fluorescence indicates the disintegration of the vesicles and the controlled release of the hydrophilic content. After 6 hours of incubation, only few cells show fluorescence, whereas after 24 hours, almost 80% of the cells show significant fluorescence. The polymer vesicles are stable inside the cells for at least 6-12 hours and are degraded after 1 day. The encapsulated content is released in a controlled way. In graphs A-C, the number of untreated living cells was normalized to 1.0; the error bars represent the standard deviation over a series of experiments; curves represent the mathematical approximation to the data; in A-C, the x-axis is logarithmic.
q 2008 Lippincott Williams & Wilkins FIGURE 5. Cytotoxicity evaluation. Rat skeletal muscle cells were incubated with high concentrations of pravastatin-containing polymer vesicles or free pravastatin to determine toxic effects of the drug with two different assays (see Methods section for details). The free pravastatin shows strong acute toxic effects in concentrations necessary to inhibit macrophage endocytic activity with an estimated LD50 (dosage that induces cell death in half of the myocyte population) of 4 to 5 times ED50. The polymer vesicles containing encapsulated pravastatin on the other hand show no significant toxic effects in this assay even at concentrations up to 15 times ED50. (The number of untreated living cells was normalized to 1.0; curves represent the mathematical approximation to the data).
